DK3027656T3 - Medikament, der omfatter anti-phospholipase d4-antistof - Google Patents

Medikament, der omfatter anti-phospholipase d4-antistof Download PDF

Info

Publication number
DK3027656T3
DK3027656T3 DK14761423.4T DK14761423T DK3027656T3 DK 3027656 T3 DK3027656 T3 DK 3027656T3 DK 14761423 T DK14761423 T DK 14761423T DK 3027656 T3 DK3027656 T3 DK 3027656T3
Authority
DK
Denmark
Prior art keywords
phospholipase
antibody
containing anti
medication containing
medication
Prior art date
Application number
DK14761423.4T
Other languages
Danish (da)
English (en)
Inventor
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Application granted granted Critical
Publication of DK3027656T3 publication Critical patent/DK3027656T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK14761423.4T 2013-07-30 2014-07-30 Medikament, der omfatter anti-phospholipase d4-antistof DK3027656T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (1)

Publication Number Publication Date
DK3027656T3 true DK3027656T3 (da) 2019-08-05

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14761423.4T DK3027656T3 (da) 2013-07-30 2014-07-30 Medikament, der omfatter anti-phospholipase d4-antistof

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG10201800592SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
SG10201800592SA (en) * 2013-07-30 2018-03-28 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
AU2019208102B2 (en) 2018-01-12 2025-10-09 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型tlr7の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
EP1392855A4 (en) * 2000-12-07 2005-05-25 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
SG10201800592SA (en) * 2013-07-30 2018-03-28 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
WO2015016386A1 (en) 2015-02-05
MX2016001193A (es) 2016-05-26
JP2016534022A (ja) 2016-11-04
AU2014297217B2 (en) 2020-01-16
MX381725B (es) 2025-03-13
RU2016106708A3 (enExample) 2018-03-30
US20160168266A1 (en) 2016-06-16
JP6843449B2 (ja) 2021-03-17
CA2919736C (en) 2022-03-22
CN105745226A (zh) 2016-07-06
CN105745226B (zh) 2020-03-06
JP2019214621A (ja) 2019-12-19
ES2736324T3 (es) 2019-12-27
BR112016002001A2 (pt) 2017-08-29
SG11201600666SA (en) 2016-02-26
KR20160034934A (ko) 2016-03-30
JP2019014759A (ja) 2019-01-31
CA2919736A1 (en) 2015-02-05
SG10201800592SA (en) 2018-03-28
BR112016002001B1 (pt) 2023-04-25
TR201910330T4 (tr) 2019-07-22
HUE044469T2 (hu) 2019-10-28
KR102367760B1 (ko) 2022-02-24
EP3027656A1 (en) 2016-06-08
US20210130493A1 (en) 2021-05-06
RU2016106708A (ru) 2017-09-01
JP6431523B2 (ja) 2018-11-28
PL3027656T3 (pl) 2019-10-31
AU2014297217A1 (en) 2016-02-18
RU2709741C2 (ru) 2019-12-19
EP3027656B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
FR3006466B3 (fr) .
FR3007989B1 (fr) Autoinjecteur.
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
FR3013601B1 (fr) Autoinjecteur.
DK3027656T3 (da) Medikament, der omfatter anti-phospholipase d4-antistof
FR3001302B1 (fr) .
ES1086107Y (es) Contenedor armable.
FR3001303B1 (fr) .
BR302013006684S1 (pt) Configuração aplicada em garrafa.
BR302013002358S1 (pt) Configuração aplicada em frasco.
TH148359B (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
UA27144S (uk) Пляшка
UA26504S (uk) Пляшка
UA26588S (uk) Пляшка
UA26699S (uk) Пляшка
ITBS20130045U1 (it) Bottiglia barrique
UA27140S (uk) Пляшка
UA26297S (uk) Пляшка
UA28063S (uk) Пляшка
UA27836S (uk) Пляшка
UA27824S (uk) Пляшка
UA26130S (uk) Пляшка
UA27562S (uk) Пляшка
UA25509S (uk) Пляшка